Jefferies Maintains a 'Buy' on Pfizer (PFE); First Half Sweet Spot Ahead of H2'12 Pipeline Casino
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $28.55 +0.32%
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Pfizer (NYSE: PFE) price target raised from $25 to $26.
Jefferies analyst said, "We see strong potential for outperformance in H1'12 driven by the likely approval of a best-in-class label for Eliquis and increasing visibility on the Animal Health and Nutrition disposals. We have become incrementally concerned over tofacitinib's safety profile recently and see asymmetric downside risk for an on-time approval. Meanwhile, bapineuzumab provides substantial positive asymmetry versus our current assumptions."
"Management lowered 2012 Non-GAAP EPS guidance to $2.20-$2.30 (prior $2.25-$2.35) due to FX headwinds. Our updated 2012E estimates for revenue and Non-GAAP EPS are $63.46bn (Cons. $62.98bn) and $2.27 (Cons. $2.30; guidance $2.20 - $2.30), respectively."
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.11 yesterday.
Jefferies analyst said, "We see strong potential for outperformance in H1'12 driven by the likely approval of a best-in-class label for Eliquis and increasing visibility on the Animal Health and Nutrition disposals. We have become incrementally concerned over tofacitinib's safety profile recently and see asymmetric downside risk for an on-time approval. Meanwhile, bapineuzumab provides substantial positive asymmetry versus our current assumptions."
"Management lowered 2012 Non-GAAP EPS guidance to $2.20-$2.30 (prior $2.25-$2.35) due to FX headwinds. Our updated 2012E estimates for revenue and Non-GAAP EPS are $63.46bn (Cons. $62.98bn) and $2.27 (Cons. $2.30; guidance $2.20 - $2.30), respectively."
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $21.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Science Applications (SAIC) PT Raised to $140 at Jefferies
- Raymond James Starts Mercantile Bank Corporation (MBWM) at Outperform
- Raymond James Starts Southern Missouri Bancorp (SMBC) at Market Perform
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
